PE20050206A1 - Composicion farmaceutica que contiene un inhibidor de histona deacetilasa - Google Patents

Composicion farmaceutica que contiene un inhibidor de histona deacetilasa

Info

Publication number
PE20050206A1
PE20050206A1 PE2004000533A PE2004000533A PE20050206A1 PE 20050206 A1 PE20050206 A1 PE 20050206A1 PE 2004000533 A PE2004000533 A PE 2004000533A PE 2004000533 A PE2004000533 A PE 2004000533A PE 20050206 A1 PE20050206 A1 PE 20050206A1
Authority
PE
Peru
Prior art keywords
pharmaceutical composition
amino
inhibitor
composition containing
deacetilase
Prior art date
Application number
PE2004000533A
Other languages
English (en)
Spanish (es)
Inventor
Osamu Nakanishi
Tatsuo Sugawara
Hideyuki Migita
Yasuhiro Matsuba
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of PE20050206A1 publication Critical patent/PE20050206A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
PE2004000533A 2003-05-26 2004-05-25 Composicion farmaceutica que contiene un inhibidor de histona deacetilasa PE20050206A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2003148073 2003-05-26

Publications (1)

Publication Number Publication Date
PE20050206A1 true PE20050206A1 (es) 2005-03-26

Family

ID=33475383

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2004000533A PE20050206A1 (es) 2003-05-26 2004-05-25 Composicion farmaceutica que contiene un inhibidor de histona deacetilasa

Country Status (27)

Country Link
US (1) US20070098816A1 (enExample)
EP (1) EP1626719A1 (enExample)
JP (1) JP2006526031A (enExample)
KR (1) KR100938712B1 (enExample)
CN (2) CN1794991A (enExample)
AR (1) AR045318A1 (enExample)
AU (1) AU2004241873C1 (enExample)
BR (1) BRPI0410959A (enExample)
CA (4) CA2527191A1 (enExample)
CL (1) CL2004001278A1 (enExample)
CO (1) CO5660262A2 (enExample)
CR (1) CR8163A (enExample)
CU (1) CU23490B7 (enExample)
EC (1) ECSP056253A (enExample)
IL (1) IL171941A0 (enExample)
ME (1) MEP32308A (enExample)
MX (1) MXPA05012345A (enExample)
NO (1) NO20055417L (enExample)
NZ (1) NZ543591A (enExample)
PE (1) PE20050206A1 (enExample)
RS (1) RS20050884A (enExample)
RU (1) RU2322971C2 (enExample)
TW (1) TW200505424A (enExample)
UA (1) UA81499C2 (enExample)
UY (1) UY28330A1 (enExample)
WO (1) WO2004103369A1 (enExample)
ZA (1) ZA200509515B (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US20030129724A1 (en) 2000-03-03 2003-07-10 Grozinger Christina M. Class II human histone deacetylases, and uses related thereto
US7244853B2 (en) 2001-05-09 2007-07-17 President And Fellows Of Harvard College Dioxanes and uses thereof
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7375228B2 (en) 2003-03-17 2008-05-20 Takeda San Diego, Inc. Histone deacetylase inhibitors
DE602004027824D1 (de) 2003-09-25 2010-08-05 Astellas Pharma Inc Antitumorales mittel mit einem histon-deacetylase-hemmer und einem topoisomerase-ii-hemmer
EP1712552A1 (en) * 2005-04-11 2006-10-18 INDENA S.p.A. Semisynthesis process for the preparation of 10-deacetyl-n-debenzoyl-paclitaxel
US7446126B2 (en) * 2004-10-08 2008-11-04 Indena S.P.A. Semisynthesis process for the preparation of 10-deacetyl-N-debenzoyl-paclitaxel
US7642275B2 (en) 2004-12-16 2010-01-05 Takeda San Diego, Inc. Histone deacetylase inhibitors
JP2008533053A (ja) * 2005-03-11 2008-08-21 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド ヒストン脱アセチル化酵素阻害剤は、がん細胞を上皮増殖因子受容体阻害剤に対して感受性にする
SG171690A1 (en) 2005-03-22 2011-06-29 Harvard College Treatment of protein degradation disorders
JP2008540574A (ja) 2005-05-11 2008-11-20 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
CA2615105A1 (en) 2005-07-14 2007-01-25 Takeda San Diego, Inc. Histone deacetylase inhibitors
WO2008091349A1 (en) 2006-02-14 2008-07-31 The President And Fellows Of Harvard College Bifunctional histone deacetylase inhibitors
DK2010168T3 (da) 2006-02-14 2014-07-21 Harvard College Histondeacetylase-inhibitore
WO2007130429A2 (en) 2006-05-03 2007-11-15 The President And Fellows Of Harvard College Histone deacetylase and tubulin deacetylase inhibitors
GB0625283D0 (en) * 2006-12-19 2007-01-24 Cyclacel Ltd Combination
PT2099442E (pt) * 2006-12-26 2015-02-10 Pharmacyclics Inc Métodos de utilização de inibidores de histona desacetilase e monitorização de biomarcadores em terapia de combinação
WO2009067453A1 (en) * 2007-11-19 2009-05-28 Syndax Pharmaceuticals, Inc. Combinations of hdac inhibitors and proteasome inhibitors
US8293513B2 (en) * 2007-12-14 2012-10-23 Georgetown University Histone deacetylase inhibitors
EP2321264B1 (en) 2008-07-23 2016-05-04 President and Fellows of Harvard College Deacetylase inhibitors and uses thereof
GB2462893B (en) * 2008-08-29 2010-10-13 Bayer Schering Pharma Ag N-(2-aminophenyl)-4-[N-(pyridine-3-yl)-methoxycarbonyl-aminomethyl]-benzamide (MS-275) polymorph B
RS52164B (sr) * 2008-08-29 2012-08-31 Bayer Pharma Aktiengesellschaft N-(2-aminofenil)-4-[n-(piridin-3-il)-metoksikarbonilaminometil]-benzamid (ms-275)polimorf b
PL3354650T3 (pl) 2008-12-19 2022-06-13 Vertex Pharmaceuticals Incorporated Związki przydatne jako inhibitory kinazy atr
US20120034302A1 (en) * 2009-02-11 2012-02-09 Liangping Yu Particulate composition and the method of making the same
WO2010125462A2 (en) * 2009-05-01 2010-11-04 Oncozyme Pharma Inc. Pentamidine combinations for treating cancer
CA2763786C (en) * 2009-06-08 2014-09-30 Gilead Sciences, Inc. Alkanoylamino benzamide aniline hdac inihibitor compounds
US8716344B2 (en) 2009-08-11 2014-05-06 President And Fellows Of Harvard College Class- and isoform-specific HDAC inhibitors and uses thereof
BR112012004149A2 (pt) * 2009-08-25 2016-03-22 Abraxis Bioscience Llc terapia de combinação com composições de nanopartículas de taxano e inibidores de hedgehog
JP5836367B2 (ja) 2010-05-12 2015-12-24 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼ阻害剤として有用な化合物
UA110853C2 (uk) 2011-09-13 2016-02-25 Фармасайклікс, Інк. Лікарські форми інгібітора гістондеацетилази у комбінації з бендамустином та їхнє застосування
AU2012315384B2 (en) 2011-09-30 2017-08-10 Vertex Pharmaceuticals Incorporated Treating pancreatic cancer and non-small cell lung cancer with ATR inhibitors
RU2018147217A (ru) 2011-09-30 2019-01-18 Вертекс Фармасьютикалз Инкорпорейтед Способы получения соединений, которые можно использовать в качестве ингибиторов киназы atr
WO2013085902A1 (en) * 2011-12-05 2013-06-13 The University Of Texas M.D. Combination therapy methods for treating an inflammatory breast cancer
CN104582795B (zh) 2012-04-05 2018-04-20 沃泰克斯药物股份有限公司 可用作atr激酶抑制剂的化合物及其组合疗法
DK2904406T3 (en) 2012-10-04 2018-06-18 Vertex Pharma METHOD OF DETERMINING THE ATR INHIBITION, INCREASED DNA DAMAGE
JP6320506B2 (ja) 2013-03-12 2018-05-09 セルジーン クオンティセル リサーチ，インク． ヒストンデメチラーゼ阻害剤
US9963452B2 (en) * 2013-03-14 2018-05-08 Augusta Pharmaceuticals Inc. Methods, compounds, and compositions for inhibition of ROS
EA201592012A8 (ru) * 2014-02-21 2018-10-31 Общество С Ограниченной Ответственностью "Биолаб 612" Применение флагеллина для улучшенной химиотерапии
SG11201702119PA (en) 2014-09-17 2017-04-27 Quanticel Pharmaceuticals Inc Histone demethylase inhibitors
US11464774B2 (en) 2015-09-30 2022-10-11 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
US11596612B1 (en) 2022-03-08 2023-03-07 PTC Innovations, LLC Topical anesthetics
WO2025041160A1 (en) * 2023-08-19 2025-02-27 Birla Institute Of Technology And Science (Bits), Pilani Bifunctional conjugate molecules for cancer treatment and process of making the same

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US6794392B1 (en) * 1996-09-30 2004-09-21 Schering Aktiengesellschaft Cell differentiation inducer
US6174905B1 (en) * 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
JP3354090B2 (ja) * 1996-09-30 2002-12-09 シエーリング アクチエンゲゼルシャフト 分化誘導剤
US5753637A (en) * 1996-10-09 1998-05-19 Ideal Ideas, Inc. Method of treating acne conditions
PT1115391E (pt) * 1998-09-25 2003-02-28 Warner Lambert Co Quimioterapia do cancro com acetildinalina em combinacao com gemcitabina capecitabina ou cisplatina
AU4144400A (en) * 1999-04-27 2000-11-10 Mitsubishi Pharma Corporation Preventives/remedies for liver diseases
IL149363A0 (en) * 1999-11-10 2002-11-10 Warner Lambert Co Combination chemotherapy
US6905669B2 (en) * 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
CZ20022216A3 (cs) * 2001-07-02 2003-05-14 Warner-Lambert Company Kombinační chemoterapie
JP2003137866A (ja) * 2001-11-01 2003-05-14 Sankyo Co Ltd フェニレンジアミン誘導体

Also Published As

Publication number Publication date
ZA200509515B (en) 2006-07-26
NO20055417L (no) 2005-12-19
RU2005140570A (ru) 2006-06-10
KR20060009371A (ko) 2006-01-31
TW200505424A (en) 2005-02-16
JP2006526031A (ja) 2006-11-16
CN101322707A (zh) 2008-12-17
CR8163A (es) 2006-07-14
RU2322971C2 (ru) 2008-04-27
US20070098816A1 (en) 2007-05-03
AU2004241873B8 (en) 2008-05-29
MEP32308A (en) 2010-10-10
EP1626719A1 (en) 2006-02-22
CA2634709A1 (en) 2004-12-02
ECSP056253A (es) 2006-10-25
RS20050884A (sr) 2008-04-04
NO20055417D0 (no) 2005-11-16
CU23490B7 (es) 2010-02-23
AR045318A1 (es) 2005-10-26
AU2004241873A1 (en) 2004-12-02
AU2004241873B2 (en) 2008-05-08
BRPI0410959A (pt) 2006-07-04
MXPA05012345A (es) 2006-02-08
CA2527191A1 (en) 2004-12-02
CO5660262A2 (es) 2006-07-31
KR100938712B1 (ko) 2010-01-25
CL2004001278A1 (es) 2005-05-06
CN1794991A (zh) 2006-06-28
UA81499C2 (en) 2008-01-10
NZ543591A (en) 2009-09-25
IL171941A0 (en) 2006-04-10
WO2004103369A1 (en) 2004-12-02
AU2004241873C1 (en) 2009-01-22
UY28330A1 (es) 2004-12-31
CA2634765A1 (en) 2004-12-02
CA2634766A1 (en) 2004-12-02

Similar Documents

Publication Publication Date Title
ECSP20027480A (es) Indolil alquil amino derivados sustituidos como nuevos inhibidores de la histona desacetilasa
ECSP045253A (es) Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa
SE0202133D0 (sv) Novel compounds
BR0313160A (pt) Composto, composição farmacêutica, métodos para tratar uma condição e um neoplasmo suscetìvel em um animal em um animal, processo para preparar um composto e uso de um composto
CY1116103T1 (el) Υποκατεστημενα παραγωγα 1,2,3,4-τετραϋδροϊσοκινολινης
UY30316A1 (es) Derivados sustituidos de benzamidas, nicotinamidas, propanamidas, acetamidas y carboxamidas n-(2-(piperidin-1-ilmetil)ciclohexil)sustituidas, procesos de preparacion, composiciones conteniéndolos y aplicaciones
ECSP055582A (es) Derivados de benzotiazol que tienen actividad agonista de beta-2-adrenorreceptor
CO5690607A2 (es) Compuestos de piridina como inhibidores de dipeptidil peptidasa iv
BRPI0015254C1 (pt) compostos derivados de carbamoiloxialquil-azólio, seu uso, bem como composição farmacêutica compreendendo os mesmos.
BRPI0515477A (pt) derivados heterocìclicos bicìclicos e o uso dos mesmos como inibidores de estaroil-coa-desaturase (scd)
ATE419848T1 (de) Cycloalkyl-lactam-derivate als inhibitoren von 11-beta-hydroxysteroiddehydrogenase 1
DK1697371T3 (da) Azabicykliske heterocykliske forbindelser som cannabinoidreceptormodulatorer
BRPI0617167B8 (pt) sulfonilpirróis como inibidores de hdac's, seu uso, composição farmacêutica e combinação
PE20081362A1 (es) DERIVADOS MORFOLINO PIRIMIDINA COMO INHIBIDORES DE mTOR QUINASA Y PI3K
SE0302811D0 (sv) Novel compounds
CO5660262A2 (es) Composicion farmaceutica que contiene un inhibidor de histona deacetilasa
NO20082269L (no) Nye piperaziner som antimalariamidler
EA200700096A1 (ru) Производные 2-карбамид-4-фенилтиазола, способ их получения и их применение в терапии
SA522431498B1 (ar) مشتقات 3، 6-داي أمينو-بيريدازين-3-يل، تركيبات صيدلية تحتوي عليها واستخدامها في صورة عوامل مساعدة على تلاشي الخلايا
BRPI0713132B8 (pt) compostos derivados de cinamoil-piperazina, método de preparação dos referidos compostos, composições farmacêuticas, seus usos como antagonistas de par-i e produtos
NO20054340L (no) Nye sammenkoplede heterocykler og deres anvendelse
ES2335410T8 (es) Derivados de aminopropanol.
SE0303541D0 (sv) New compounds
UY29732A1 (es) Derivados de benzotiazolonas, procesos de preparación, composiciones y combinaciones que los contienen y aplicaciones
NI200900147A (es) Nuevos derivados tricíclicos su procedimiento de preparación y las composiciones farmacéuticas que los contienen.

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed